查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1392004

凝血酶抑制剂市场：按类型、按应用、按地区

Thrombin Inhibitor Market, By Type, By Application (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Others ), By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年全球凝血酶抑制剂市场规模为307.5亿美元，2023-2030年预测期间复合年增长率为6.2%，2030年将达468.5亿美元。

报告范围 报告详情
基准年 2022年 2023年市场规模 307.5亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 6.20% 2030年市场规模预测 468.5亿美元
图 1. 2023 年按地区分類的凝血酶抑制剂的全球市场占有率(%)
凝血酶抑制剂市场-IMG1

凝血酶抑制剂是一种抗凝血剂（或起抗凝血剂作用的一类药物），可与凝血酶结合并抑制其活性，从而防止血栓形成。用于预防动、静脉血栓症，预防及治疗深层静脉栓塞症，预防心房颤动时的血栓性栓塞症。

凝血酶抑制剂治疗的疾病包括急性冠状动脉症候群、心臟血小板减少性疾病、肝素诱发的血小板减少症（HIT）、静脉血栓栓塞症（VTE）、心房颤动（Afib）、深层静脉栓塞症（DVT）、肺动脉栓塞等。

目前医疗保健专业人员使用的直接凝血酶抑制剂包括阿加曲班（静脉注射）、比伐卢定（静脉注射）和达比加群（锭剂）。

市场动态：

深层静脉栓塞症(DVT)、肺动脉栓塞(PE) 和心房颤动(AF) 的盛行率/发生率不断增加，对安全有效治疗的需求（由于全世界人们的认识不断提高）研发(R&D) 的增加，以及新型抗凝血剂的引入是预计推动全球凝血酶抑制剂市场成长的主要因素。

例如，2018年6月，Mylan NV宣布在美国推出注射用比伐卢定，学名药。本产品为 250 mg 单剂量给药，是一种直接凝血酶抑制剂，可用作患者的抗凝血剂。在美国食品药物管理局(FDA)核准该产品的简略新药认证申请 (ANDA) 后，迈兰 (Mylan) 正在向医院和机构提供比伐卢定。

本研究的主要特点

  • 该报告对全球凝血酶抑制剂市场进行了详细分析，并列出了预测期（2023-2030）的市场规模和复合年增长率。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据以下参数（例如公司亮点、产品系列、主要亮点、绩效和策略）介绍了全球凝血酶抑制剂市场的主要企业。
  • 该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
  • 全球凝血酶抑制剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球凝血酶抑制剂市场的各种策略矩阵，将有助于相关人员做出决策。

目录：

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章凝血酶抑制剂市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章凝血酶抑制剂市场，依类型，2018-2030

  • 介绍
  • 直接凝血酶抑制剂
  • 间接凝血酶抑制剂

第六章凝血酶抑制剂市场，依应用分类，2018-2030

  • 介绍
  • 深层静脉栓塞症（DVT）
  • 肺动脉栓塞（PE）
  • 心房颤动 (AF)
  • 其他（中风预防、急性冠状动脉症候群等）

第七章凝血酶抑制剂市场，依地区，2018-2030

  • 介绍
  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第八章竞争形势

  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited

第9章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5835

The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 30.75 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.20% 2030 Value Projection: US$ 46.85 Bn
Figure 1. Global Thrombin Inhibitor Market Share (%), by Region, 2023
Thrombin Inhibitor Market - IMG1

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.

The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.

Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).

Market Dynamics:

The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

  • This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030)
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market

Detailed Segmentation:

  • By Type:
    • Direct Thrombin Inhibitors
    • Indirect Thrombin Inhibitors
  • By Application:
    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism (PE)
    • Atrial Fibrillation (AF)
    • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Eisai Co., Ltd.
    • Merck & Co., Inc.
    • Novartis International AG
    • GlaxoSmithKline plc
    • AbbVie Inc.
    • Portola Pharmaceuticals, Inc.
    • CSL Behring
    • Johnson & Johnson
    • Sanofi S.A.
    • Bayer AG
    • Pfizer Inc.
    • Bristol Myers Squibb
    • Boehringer Ingelheim GmbH
    • Daiichi Sankyo Company
    • Aspen Pharmacare Holdings Limited

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Thrombin Inhibitor, By Type
    • Market Thrombin Inhibitor, By Application
    • Market Thrombin Inhibitor, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Thrombin Inhibitor Market, By Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Direct Thrombin Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Indirect Thrombin Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Thrombin Inhibitor Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Deep Vein Thrombosis (DVT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Pulmonary Embolism (PE)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Atrial Fibrillation (AF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Thrombin Inhibitor Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

8. Competitive Landscape

  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited
  • Analyst Views

9. Section

  • Research Methodology
  • About us